EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Pharmacokinetic/Pharmacodynamic Translation and Model‐Informed Drug Development for Oligonucleotide Therapeutics

Paridhi Gupta iD, Mindy Magee iD, Vivaswath S Ayyar iD

The Journal of Clinical Pharmacology · 2026

DOI: 10.1002/jcph.70267 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Paridhi Gupta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA. Hauptthemen laut MEDLINE: Drug Development, Oligonucleotides, Antisense, Models, Biological, RNA, Small Interfering. Die Arbeit nennt 133 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) have emerged as clinically validated therapeutic modalities, with approvals and late‐stage development programs spanning rare genetic, neurologic, cardiovascular, metabolic, and infectious diseases. Despite these advances, oligonucleotide development presents unique challenges compared with small molecules and biologics, including rapid plasma distributive clearance, nuclease‐mediated degradation, limited extrahepatic distribution, and prolonged pharmacodynamic effects driven by tissue retention and intracellular mechanisms such as RNA‐induced silencing complex loading or RNase H‐mediated activity. Consequently, tissue disposition and intracellular pharmacology most often govern therapeutic response more directly than plasma exposures alone, complicating conventional approaches to dose selection, efficacy prediction, and safety assessment. Model‐informed drug development (MIDD) offers a quantitative framework to address these challenges through integration of preclinical, translational, and clinical data into empirical, mechanistic, and systems‐level models. This review summarizes current and emerging MIDD applications in oligonucleotide therapeutics, with primary emphasis on siRNAs and complementary insights from ASOs. Approaches discussed include empirical and semi‐mechanistic pharmacokinetic/pharmacodynamic (PK/PD) models, physiologically based pharmacokinetic (PBPK) frameworks describing tissue‐selective biodistribution and intracellular disposition, and quantitative systems pharmacology (QSP) models linking molecular target modulation with downstream biologic and clinical responses. Collectively, these approaches have supported cross‐species translation; human dose selection; clinical trial optimization; and mechanistic understanding of oligonucleotide absorption, distribution, metabolism, excretion, and pharmacology. Finally, we discuss future opportunities and remaining challenges for MIDD in oligonucleotide therapeutics, including enabling extrahepatic delivery, characterizing interindividual variability, and integrating systems‐level and data‐driven approaches to improve translational predictability and accelerate development of next‐generation oligonucleotide medicines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentOligonucleotides, AntisenseModels, BiologicalRNA, Small InterferingOligonucleotidesHumansAnimals

Stichwörter der Autor:innen

antisense oligonucleotidesmodel‐informed drug developmentpharmacodynamicspharmacokineticssmall interfering RNA

Substanzen

Oligonucleotides, AntisenseRNA, Small InterferingOligonucleotides

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA.
  • GSK, Collegeville, PA, USA.

ORCID-Profile: Paridhi Gupta, Mindy Magee, Vivaswath S Ayyar

Zitieren

APA

Gupta, P., Magee, M., & Ayyar, V. S. (2026). Pharmacokinetic/Pharmacodynamic Translation and Model‐Informed Drug Development for Oligonucleotide Therapeutics. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70267

Vancouver

Gupta P, Magee M, Ayyar VS. Pharmacokinetic/Pharmacodynamic Translation and Model‐Informed Drug Development for Oligonucleotide Therapeutics. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70267

BibTeX
@article{Gupta2026,
  author = {Gupta, Paridhi and Magee, Mindy and Ayyar, Vivaswath S},
  title = {Pharmacokinetic/Pharmacodynamic Translation and Model‐Informed Drug Development for Oligonucleotide Therapeutics},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/jcph.70267}
}
Kostenlos starten →